Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III benvitimod cream trial in mild to moderate atopic dermatitis
ChiCTR2200059419Phase 3Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tapinarof in atopic dermatitis (AD) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: IGA response at Week 8, Recurrence rate and time to first recurrence and 2 more. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2200059419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059419.